Clinical Trial

Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies

Study acronym: MALMBA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, single arm, multicenter study to evaluate the feasibility of maribavir treatment in multiple myeloma and lymphoma patients undergoing bispecific antibody treatment and experiencing treatment emergent CMV events
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-02.
Status change: Not Yet Recruiting → Recruiting 2025-11-26
Trial Details
NCT Number NCT07014319
Lead Sponsor Seoul National University Hospital
Conditions Cytomegalovirus (CMV)
Enrollment 20 participants
Start Date 2025-11-03
Primary Completion 2027-10-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-04